What other fully human antibody discovery platforms does ProBio offer?

In addition to our Human Fab naïve library, ProBio offers multiple platforms for fully human antibody discovery, including transgenic mouse models (conventional IgG and heavy-chain-only mice). These platforms can be integrated with hybridoma, single B cell screening, and phage display technologies, providing flexible solutions tailored to your target, timeline, and project goals, allowing you to access the optimal discovery strategy for diverse targets and applications.

How does your human naïve Fab library compare to synthetic libraries, immune libraries, and transgenic mouse platforms?

Each antibody discovery method has unique advantages, but ProBio's human naïve Fab library provides the strongest overall balance of speed, quality, and cost: ProBio Human Fab Naïve Library: Natural antibodies from 2,000+ human donors; fully human (no humanization); fast (~30 days); high diversity. Best balance of speed, diversity, cost, and developability. Synthetic Libraries: Engineered CDR diversity with artificial bias and higher immunogenicity risk. Suitable for large diversity screening when natural origin less critical. Immune Libraries: In vivo matured antibodies with high affinity but requires immunization, long timelines, limited for toxic/low-immunogenic targets. Best when antigen response is strong and well-defined. Transgenic Mice: Fully human antibodies with in vivo affinity maturation but long timelines (4‑5 months), higher cost, limited for membrane proteins. Best for complex targets requiring in vivo maturation.

What antigen types are supported, and what are the sample requirements?

Our Fab library platform supports a wide range of antigen types for antibody discovery, including: Proteins and peptides, Cells and membrane proteins (e.g., GPCRs, ion channels), Small molecules and polysaccharides. Typical sample requirements: Proteins: ≥1 mg, Peptides: ≥5 mg. For difficult targets, we apply tailored strategies such as cell-based panning, epitope-focused panning, and customized antigen design. We have proven capability to handle challenging and complex targets.

What deliverables are included, and who owns the antibody IP?

ProBio provides full transparency, complete data delivery, and clear IP ownership. Our complete antibody discovery package includes: Purified antibody samples (1‑5 mg), Full sequence data, Germline analysis, Affinity and characterization data, Comprehensive experimental report. For ≤10 sequences, 100% IP ownership is assigned to the customer, with no patent restrictions.

What downstream antibody development services does ProBio offer?

ProBio provides an end-to-end antibody discovery and development solution, including affinity maturation and antibody engineering, Fc engineering and optimization, full-length IgG construction, stable cell line development, pilot-scale antibody production, in vitro and in vivo functional validation and preclinical development support. We provide seamless transition from antibody discovery to development-ready candidates, helping you progress your discovery projects faster.

Human Fab Naïve Library Discovery Service

Accelerate fully human antibody discovery with ProBio’s high-diversity Fab library. Powered by phage display and advanced screening, our platform delivers high-affinity, developable antibody leads in as little as one month, helping you reduce risk, shorten timelines, and rapidly advance from target to therapeutic candidate.

Overview

Workflow

Case Studies

Related Services

FAQs

Accelerate Fully Human Antibody Discovery with Fab Libraries

High-Quality Library

A high capacity（1.5*10^11) and diverse library, built from over 2,000 human donors.

Diverse Screening Strategies

Customized panning methods and a dual-validation screening system to improve accuracy, reduce false positives, and compatible with multiple assays.

Integrated One-Stop Solution

End-to-end discovery and optimization including, affinity maturation, Fc engineering, developability assessment and in vitro and in vivo validation.

Discover Fully Human Antibodies Fast

Strategy design

Antigen preparation and QC

Enrichment panning

Monoclonal screening

Sequencing

Antibody production and validation

4-8 weeks

Faster, Reliable Antibody Discovery and Lead Optimization.

Rapid Delivery

1 month

Access high diversity fully human antibodies
Phage display offers a faster and cost effective alternative to animal models

More Sequence Diversity

2,000+ donors

Access high diversity fully human antibodies
Insertion rate exceeding 98%, in-frame rate over 90%
Sequence diversity greater than 98%

Improved Screening

Dual-validation

Proprietary vector system enabling screening on monoclonal phage and soluble fragments
Combined validation schemes (binding/blocking ELISA/FACS, SPR ranking)

Case Studies

High-Specificity CLDN18.2 Antibody Discovery Using Human Fab Library

Rapid discovery of high-quality PD-L1 antibody leads with human Fab library

Rapid Discovery of High-Quality PD-L1 Antibody Leads Using a Human Fab Library

Resources

BROCHURE

Biologics Discovery Services Brochure

Tailored discovery strategies for diverse biologics modalities, designed to enhance success rates.

Learn More

Webinar on functional antibody lead discovery at early screening stage

HAND
BOOK

Discovery of Functional Antibody Leads at Early Stage of Lead Screening

Solutions to obtain more functional leads at an earlier stage.

Learn More

Affinity maturation service brochure using PML and HTP FASEBA screening

POSTER

Achieving High Affinity by Affinity Maturation

Utilization of PML and HTP FASEBA screening platform for antibody affinity improvements.

Learn More

HAND
BOOK

Antibody Lead Optimization Service

Learn more about how to accelerate antibody candidates with our lead optimization services.

Learn More

Request a Quote

Bring the Most Promising Candidates Forward with Confidence.

Request More Information

Human Fab Naïve Library Discovery Service